Potassium should be monitored during treatment of many conditions but especially in diabetic ketoacidosis and any intravenous therapy for fluid replacement. Used in the evaluation of electrolyte balance, cardiac arrythmia, muscular weakness, hepatic encephalopathy, and renal failure.
Used as an ancillary test for congenital adrenal hyperplasia, particularly in situations in which a diagnosis of 21-hydroxylase and 11-hydroxylase deficiency have been ruled out. Useful for confirming a diagnosis of 3-beta-hydroxy dehydrogenase deficiency.
Useful in the diagnosis of bacteremia and septicemia in adults and children (including neonates), the diagnosis of renal involvement in urinary tract infection in children, the diagnosis of bacterial infection in neutropenic patients, the diagnosis, risk stratification, and monitoring of septic shock, the diagnosis of systemic secondary infection post-surgery (and in severe trauma, burns, and multiorgan failure). Also useful in the differential diagnosis of bacterial versus viral meningitis, and community-acquired bacterial versus viral pneumonia. Also helpful for the monitoring of therapeutic response to antibacterial therapy.
Green - Lithium Heparin (2)
Allow specimen to clot for at least 15 minutes post-draw. Centrifuge and seperate serum from red cells within 2 hours of collection. Submit unopened tube refrigerated.
Must centrifuge within 2 hours of collection. The same specimen type (serum, plasma) should be used throughout the patient's clinical course.
Useful for predicting recurrence after radical prostatectomy for clinically localized prostate cancer and following response to androgen ablation therapy, when used in conjunction with prostate-specific antigen.
Must obtain specimen before (or 48 hours post) rectal examination, biopsy, prostatectomy, or prostatic massage.
Useful as an initial test for evaluating patients suspected of having congenital protein C deficiency, including those with personal or family histories of thrombotic events, and for detecting and confirming congenital type I and type II protein C deficiencies. Also useful for detecting and confirming congenital homozygous protein C deficiency, and for identifying decreased functional protein C of acquired origin (eg, due to oral anticoagulant effect, vitamin K deficiency, liver disease, intravascular coagulation and fibrinolysis/disseminated intravascular coagulation).
Lt. Blue (1)
Please note if PT is being treated with Coumadin. Spin TWICE and freeze plasma within 4 hours of collection.
Useful for differentiating congenital type I protein C deficiency from type II deficiency, for evaluating the significance of decreased functional protein C, especially when decreased protein C activity might be congenital rather than acquired (eg, due to oral anticoagulant effect, vitamin K deficiency, liver disease, or intravascular coagulation and fibrinolysis/disseminated intravascular coagulation). This test is not useful for predicting a thrombotic event.
Useful for evaluating patients with a history of venous thromboembolism, and as a second-order testing for diagnosis of congenital or acquired protein S deficiency. For example, as an adjunct to initial testing based on results of protein S antigen assay (free protein S antigen, with or without total protein S antigen assay).
Lt. Blue (1)
PT cannot be receiving Coumadin. Spin TWICE and freeze plasma immediately.
Direct mutation analysis for the prothrombin (PT) 20210A allele should be reserved for patients with clinically suspected thrombophilia. There may be additional indications for direct PT 20210A mutation testing, such as in determining the duration of anticoagulation therapy of venous thromboembolism patients and screening for women contemplating hormone therapy.
RT (5 Days)
Hologic invader Assay
Factor II 20210 mutation, Prothrombin 20210 mutation, Prothrombin Nucleotide, PTNT
Useful for assessing the risk of prostate cancer in patients with borderline or moderately increased total PSA (4.0-10.0 ng/mL) , and for determining which patients should have follow-up prostate biopsy.
Avoid biotin (B7) for 12 HR prior to collection. Pour off serum within 3 hours of collection and freeze.
FREEZE (90 Days)
Electrochemiluminescence Immunoassay (ECLIA)
Free PSA, PSA Free/Total Ratio, PSA Total and Free, PSA Ratio